ACTU Stock Analysis: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$2.91
-0.06 (-2.02%)
▼
5d:
-12.87%
30d:
+35.35%
90d:
-31.37%
WAIT
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 21, 2026
6d
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ACTU this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACTU is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACTU is down 12.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $2.91, which is considered slightly high relative to its 30-day fair value range of $2.13 to $3.07.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $2.74, while resistance sits at $3.43.
Market Sentiment: ACTU has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.50 (+354.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $2.74, while resistance sits at $3.43.
Market Sentiment: ACTU has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $13.50 (+354.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.13 -
$3.07
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.9%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 354.5% below Wall St target ($13.50)
- WARNING: Recommendation downgraded due to -12.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.13 -
$3.07
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.74
Resistance Level
$3.43
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.50
Wall Street Target
$13.50
(+354.5%)
Share & Embed Analysis
Last updated: May 14, 2026 1:06 PM ET
Data refreshes hourly during market hours. Next update: 2:06 PM
Data refreshes hourly during market hours. Next update: 2:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Todd S Thomson
SELL
280000 shares
2026-01-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 67 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$242 | 66 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
